BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Phase 2

Completed

Conditions: Smoldering Multiple Myeloma

Interventions: Biological: Elotuzumab (BMS-901608; HuLuc63)

First Posted Date: 2011-09-28

Last Posted Date: 2018-01-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 41

Registration Number: NCT01441973

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸
Winship Cancer Institute., Atlanta, Georgia, United States

and more 9 locations

Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Abatacept (BMS-188667)

First Posted Date: 2011-09-23

Last Posted Date: 2014-03-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 223

Registration Number: NCT01439204

Locations: 🇺🇸
Icon Clinical Pharmacology Unit, Llc, Omaha, Nebraska, United States

Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

Phase 2

Completed

Conditions: Hepatitis B Virus
HBV

Interventions: Drug: Entecavir
Drug: Lamivudine

First Posted Date: 2011-09-22

Last Posted Date: 2012-08-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1053

Registration Number: NCT01438424

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: Daclatasvir
Drug: Asunaprevir
Drug: Pegylated interferon alfa-2a
Drug: Ribavirin

First Posted Date: 2011-09-02

Last Posted Date: 2016-05-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 276

Registration Number: NCT01428063

Locations: 🇺🇸
Scpmg/ Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸
University Of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 18 locations

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Phase 2

Terminated

Conditions: Hepatitis C

Interventions: Drug: INX-08189
Drug: Placebo matching with INX-08189
Drug: Ribavirin
Biological: Pegylated interferon alfa-2a
Drug: Daclatasvir

First Posted Date: 2011-08-30

Last Posted Date: 2015-11-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 210

Registration Number: NCT01425970

Locations: 🇺🇸
Alamo Medical Research, San Antonio, Texas, United States
🇺🇸
Options Health Research, Llc, Tulsa, Oklahoma, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States

and more 3 locations

Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: BMS-833923 (XL139)

First Posted Date: 2011-08-10

Last Posted Date: 2013-06-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT01413906

Locations: 🇯🇵
Local Institution, Kashiwa-shi, Chiba, Japan

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

Phase 1

Completed

Conditions: HIV

Interventions: Drug: Atazanavir (POU2)
Drug: Atazanavir (current formulation)
Drug: Atazanavir, powder for oral use 1 (POU1)

First Posted Date: 2011-07-28

Last Posted Date: 2013-06-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT01404572

Locations: 🇺🇸
Pra International, Lenexa, Kansas, United States

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: BMS-817399

First Posted Date: 2011-07-28

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 123

Registration Number: NCT01404585

Locations: 🇺🇸
Pharma Resource, East Providence, Rhode Island, United States
🇺🇸
Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States
🇪🇸
Local Institution, Sevilla, Spain

and more 3 locations

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Ipilimumab (BMS-734016)
Drug: Vemurafenib

First Posted Date: 2011-07-22

Last Posted Date: 2015-01-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT01400451

Locations: 🇺🇸
University Of California Los Angeles, Los Angeles, California, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana Farber Cancer Inst, Boston, Massachusetts, United States

and more 1 locations

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

Phase 1

Completed

Conditions: Depression

Interventions: Drug: Placebo matching BMS-820836
Drug: BMS-820836

First Posted Date: 2011-07-18

Last Posted Date: 2013-06-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 57

Registration Number: NCT01396252

Locations: 🇯🇵
Local Institution, Taito-Ku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy